Innovate Ocular Oncology

Innovate Ocular Oncology continues the tradition of the INNOVATE series, bringing together scientific, clinical, and industry leaders to educate and inform participants on the latest advancements and future trends in ocular oncology. This gathering is particularly significant as the field faces critical challenges, including treatment burdens, toxicities, and access to care, despite the recent approvals of new therapies and an increase in clinical trial options. The event aims to confront these issues directly through a combination of provocative lectures, cutting-edge research presentations, and engaging panel discussions led by prominent figures in the biopharmaceutical industry. Key topics to be explored include the new applications of liquid biopsy, adjuvant and neoadjuvant therapeutics in uveal melanoma, addressing unmet needs following recent FDA approvals in ocular oncology, and strategies for tailoring therapy in complex diseases such as intraocular lymphoma. Additionally, discussions will revolve around radiation toxicities, the management of drug toxicities highlighted by black box warnings, and innovative management strategies to enhance patient care. Attendees will include ocular oncologists, ophthalmologists, medical oncologists, ocular pathologists, radiation oncologists, pediatric oncologists, anterior segment and retina specialists, biopharma representatives, translational scientists, as well as patients and patient advocates. The Innovate Retina series is a collaborative effort with iVista Medical Education, Inc.